Lennox-Gastaut Syndrome (LGS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Lennox-Gastaut syndrome (LGS) is a rare and severe form of epilepsy that begins in childhood. It belongs to the group of severe infantile epileptic syndrome (epileptic neonatal encephalopathy with suppression-burst, West syndrome, severe myoclonic epilepsy of infancy). People with Lennox-Gastaut syndrome start having seizures when they are young, usually between the ages of 3 and 5. LGS is also a physically dangerous epilepsy syndrome for children and teenagers due to frequent falls, injuries, and cognitive impairment, which can severely limit one's quality of life. Children with infantile spasms or underlying brain disorders may be affected, but the cause can also be idiopathic. Antecedent conditions associated with LGS almost always involve the cerebral cortex. The cerebral cortex and the corpus callosum produce some of the phenomena of LGS. Among lesional causes, those involving both frontal lobes most commonly lead to LGS development. However, any brain damage may be associated with LGS, and this lack of specificity has impeded the clarification of neurophysiological mechanisms.
- The incidence of Lennox-Gastaut syndrome is very low, with ~1% of childhood epilepsies in children <10 years old. About 68% of the LGS is mainly accounted for by children under the age of 18 years, and the adult population accounts for the remaining 38% of the LGS.
- It has been seen that the remission rates were the poorest for LGS; approximately 50-60% of children with infantile spasms develop other seizure types.
Thelansis’s “Lennox-Gastaut Syndrome (LGS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lennox-Gastaut Syndrome (LGS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Lennox-Gastaut Syndrome (LGS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Lennox-Gastaut Syndrome (LGS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment